Management and Outcomes of ANCA-Associated Vasculitis at a Tertiary Healthcare Facility
Table 3
Summary of induction and maintenance treatment.
Therapy
Induction, % (n = 36)
Maintenance, % (n = 36)
Relapse induction, % (n = 7)
Relapse maintenance, % (n = 7)
Cyclophosphamide
66.7 (24)
0 (0)
0 (0)
0 (0)
Rituximab
19.4 (7)
16.7 (6)
85.7 (6)
28.6 (2)
Cyclophosphamide and rituximab
2.8 (1)
0 (0)
0 (0)
0 (0)
Azathioprine
11.1 (4)
61.1 (22)
0 (0)
57.1 (4)
Corticosteroids alone
0 (0)
16.7 (6)a
14.3 (1)
14.3 (1)
Plasmapheresis
27.8 (10)
0 (0)
0 (0)
0 (0)
Mycophenolate mofetil
0 (0)
2.8 (1)
0 (0)
0 (0)
No treatment
0 (0)
2.8 (1)b
0 (0)
0 (0)
aDue to the commencement of HD or death in 4 (66.7%) of the patients, no information is available on 2 (33.3%) patients. bNot given further immunosuppression due to bowel perforation following cyclophosphamide. However, they remained clinically stable, with no worsening renal function.